Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or…

Digital Pathology and AI Highlights from ASCO 2025

Oncologists, pathologists, researchers, and industry leaders recently gathered at ASCO 2025 in Chicago to share the latest breakthroughs in cancer research and care. Among the key themes: the accelerating impact of digital pathology and AI in advancing patient outcomes and transforming R&D strategies in precision oncology. The research presented revealed a field maturing rapidly, with […]